2019
Digital Inference of Immune Microenvironment Reveals Low-Risk Subtype of Early Lung Adenocarcinoma
Kurbatov V, Balayev A, Saffarzadeh A, Heller DR, Boffa DJ, Blasberg JD, Lu J, Khan SA. Digital Inference of Immune Microenvironment Reveals Low-Risk Subtype of Early Lung Adenocarcinoma. The Annals Of Thoracic Surgery 2019, 109: 343-349. PMID: 31568747, DOI: 10.1016/j.athoracsur.2019.08.050.Peer-Reviewed Original ResearchMeSH KeywordsAdenocarcinoma of LungAdultAgedCohort StudiesDatabases, FactualDisease-Free SurvivalFemaleHumansImmunotherapyKaplan-Meier EstimateLung NeoplasmsMaleMiddle AgedNeoplasm InvasivenessNeoplasm StagingPneumonectomyPrognosisProportional Hazards ModelsRetrospective StudiesRisk AssessmentSurvival AnalysisTumor MicroenvironmentConceptsTumor immune microenvironmentImmune microenvironmentLung adenocarcinomaOverall survivalRisk groupsMast cellsCox proportional hazard modelingEarly-stage lung adenocarcinomaLow-risk subtypesKaplan-Meier analysisPathological staging systemProportional hazard modelingImproved clinical outcomesCancer immune microenvironmentImmune cell typesEarly lung adenocarcinomaActivation stateClinical outcomesValidation cohortMacrophage contentStaging systemMultivariable modelCIBERSORT analysisPatientsClinical decisionShort Tandem Repeats Define a Gestational Origin for Metastatic Choriocarcinoma
Brown K, Homer R, Baine M, Blasberg JD. Short Tandem Repeats Define a Gestational Origin for Metastatic Choriocarcinoma. The Annals Of Thoracic Surgery 2019, 108: e115-e117. PMID: 30685255, DOI: 10.1016/j.athoracsur.2018.12.038.Peer-Reviewed Original ResearchConceptsPlacenta accretaSpontaneous hemothoraxGestational choriocarcinomaLower lobe massMetastatic gestational choriocarcinomaHealthy female patientsAdjuvant therapyMetastatic choriocarcinomaSurgical explorationChief complaintFemale patientsOutside hospitalRare consequenceUnreported causeGestational originClinical implicationsChoriocarcinomaAccretaHemothoraxResectionPatientsPrognosisHospitalShortnessTherapy
2018
Depth of Muscularis Propria Invasion Does Not Prognosticate Survival in T2 Esophageal Adenocarcinoma
SEDER CW, MAHON B, HENNON M, THOMAS M, LEVEA CM, MATKOWSKYJ KA, KRISHNA M, MEDAIROS R, MACKE RA, BASU S, BLASBERG JD. Depth of Muscularis Propria Invasion Does Not Prognosticate Survival in T2 Esophageal Adenocarcinoma. Anticancer Research 2018, 38: 2195-2200. PMID: 29599339, DOI: 10.21873/anticanres.12461.Peer-Reviewed Original ResearchConceptsMuscularis propria invasionEsophageal adenocarcinomaPrognostic factorsCox proportional hazards regression analysisInferior long-term outcomesProportional hazards regression analysisPercent of patientsDisease-free survivalKaplan-Meier analysisRisk of lymphHazards regression analysisLong-term outcomesU.S. academic medical centersLong-term survivalAcademic medical centerInduction therapyMedian OSMedian ageNodal statusPerineural invasionTherapy statusSurvival differencesTumor gradeBlinded pathologistMedical Center
2016
Role of Adjuvant Therapy for Node-Negative Lung Cancer Invading the Chest Wall
Gao SJ, Corso CD, Blasberg JD, Detterbeck FC, Boffa DJ, Decker RH, Kim AW. Role of Adjuvant Therapy for Node-Negative Lung Cancer Invading the Chest Wall. Clinical Lung Cancer 2016, 18: 169-177.e4. PMID: 27890561, DOI: 10.1016/j.cllc.2016.08.005.Peer-Reviewed Original ResearchConceptsNon-small cell lung cancerAdjuvant chemotherapyAdjuvant chemoradiation therapyUnderwent surgeryChemoradiation therapyChest wall resectionRadiation therapyMargin statusTumor sizeLung cancerWall resectionNode-negative lung cancerNational Cancer Data BaseCox proportional hazards modelMargin-positive patientsChest wall invasionCell lung cancerLog-rank testStage IIB tumorsProportional hazards modelAdjuvant therapyAdjuvant treatmentOverall survivalMultivariable analysisIIB tumorsTiming of Surgery after Neoadjuvant Chemoradiation in Locally Advanced Non–Small Cell Lung Cancer
Gao SJ, Corso CD, Wang EH, Blasberg JD, Detterbeck FC, Boffa DJ, Decker RH, Kim AW. Timing of Surgery after Neoadjuvant Chemoradiation in Locally Advanced Non–Small Cell Lung Cancer. Journal Of Thoracic Oncology 2016, 12: 314-322. PMID: 27720827, DOI: 10.1016/j.jtho.2016.09.122.Peer-Reviewed Original ResearchMeSH KeywordsAdenocarcinomaCarcinoma, Large CellCarcinoma, Non-Small-Cell LungCarcinoma, Squamous CellChemoradiotherapy, AdjuvantCombined Modality TherapyFemaleFollow-Up StudiesHumansLung NeoplasmsMaleMiddle AgedNeoadjuvant TherapyNeoplasm StagingPneumonectomyPrognosisRetrospective StudiesSurvival RateTime FactorsConceptsNational Cancer Data BaseNeoadjuvant chemoradiationTiming of surgeryOverall survivalAdvanced non-small cell lung cancerNon-small cell lung cancerStage IIIA-N2 NSCLCStage IIIA NSCLCKaplan-Meier methodOverall survival rateSubset of patientsCell lung cancerLog-rank testMultivariate survival analysisProportional hazards modelIIIA NSCLCN2 NSCLCNeoadjuvant therapyTrimodality therapySurgical resectionClinical stageRetrospective studyLung cancerHazards modelSurvival rate
2015
The Surgical Apgar Score in esophagectomy
Janowak CF, Blasberg JD, Taylor L, Maloney JD, Macke RA. The Surgical Apgar Score in esophagectomy. Journal Of Thoracic And Cardiovascular Surgery 2015, 150: 806-812. PMID: 26234458, DOI: 10.1016/j.jtcvs.2015.07.017.Peer-Reviewed Original ResearchConceptsSurgical Apgar ScoreMajor morbidityApgar scorePostoperative complicationsMultivariate analysisPreoperative patient characteristicsShort-term outcomesBody mass indexStrongest predictorElective esophagectomyTranshiatal techniqueSurgical populationIntraoperative detailsIntraoperative variablesPatient characteristicsDiabetes mellitusPrimary outcomeRetrospective reviewMass indexProspective studyCare modificationsMalignant diseaseRisk factorsUnivariate analysisImproved outcomes
2010
Sublobar Resection: A Movement from the Lung Cancer Study Group
Blasberg JD, Pass HI, Donington JS. Sublobar Resection: A Movement from the Lung Cancer Study Group. Journal Of Thoracic Oncology 2010, 5: 1583-1593. PMID: 20879185, DOI: 10.1097/jto.0b013e3181e77604.Peer-Reviewed Original ResearchConceptsNon-small cell lung cancerSublobar resectionStage IA non-small cell lung cancerStage I non-small cell lung cancerMulti-institutional phase III trialLung Cancer Study GroupPostoperative lung functionSingle-institution trialLung cancer resectionCancer Study GroupHigh-risk patientsPhase III trialsEarly-stage diseaseInvasive surgical resectionCell lung cancerHigh-risk individualsMultislice computer tomographyRate of survivalPerioperative morbidityIII trialsSurgical resectionCancer resectionLung functionOncologic effectivenessRecurrence rateReduction of Elevated Plasma Osteopontin Levels With Resection of Non–Small-Cell Lung Cancer
Blasberg JD, Pass HI, Goparaju CM, Flores RM, Lee S, Donington JS. Reduction of Elevated Plasma Osteopontin Levels With Resection of Non–Small-Cell Lung Cancer. Journal Of Clinical Oncology 2010, 28: 936-941. PMID: 20085934, PMCID: PMC2834433, DOI: 10.1200/jco.2009.25.5711.Peer-Reviewed Original ResearchConceptsEarly-stage NSCLCPlasma osteopontin levelsPlasma OPN levelsOPN levelsEnzyme-linked immunosorbent assayPlasma OPNOsteopontin levelsWeeks postsurgeryElevated Plasma Osteopontin LevelsCell lung cancer correlatesUse of thoracotomyCell lung cancerLung cancer correlatesCancer-free smokersResectable NSCLCPerioperative eventsTumor characteristicsPresurgery levelsRecurrence rateValidation cohortLung cancerCancer correlatesTherapeutic responseNSCLCIndependent cohort